Analytical Data
-
基因名
NDUFA2
- Application
-
别名
Complex I-B8 ;CI-B8NADH-ubiquinone oxidoreductase B8 subunit
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43678
-
表达区间
4-99aa
-
分子量
37.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NDUFA2, or NADH:ubiquinone oxidoreductase subunit A2, is an essential component of the mitochondrial respiratory chain complex I, which plays a critical role in cellular energy production by facilitating electron transfer from NADH to ubiquinone. Research has shown that NDUFA2 is not only crucial for ATP synthesis but also for the proper function of the electron transport chain, impacting overall mitochondrial health. Mutations or dysregulation of NDUFA2 have been associated with various mitochondrial diseases, highlighting its significance in both energy metabolism and potential pathophysiological conditions. Furthermore, the study of NDUFA2 has gained traction in understanding the molecular mechanisms underlying mitochondrial dysfunction, which is linked to neurodegenerative disorders and metabolic syndromes. Recombining and characterizing the NDUFA2 protein allows for a deeper exploration of its structural and functional properties, facilitating the development of therapeutics aimed at ameliorating the effects of mitochondrial diseases. Recent advances in recombinant DNA technology have enabled researchers to produce NDUFA2 in vitro, paving the way for detailed biochemical assays and structural studies, which can provide insights into its interactions with other complex I components and its role in the regulation of mitochondrial function. As the understanding of NDUFA2 expands, it holds promise for unveiling new therapeutic strategies and biomarkers for mitochondrial-related disorders.
